Life Sciences

February 4, 2019

Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment

[vc_row][vc_column][vc_column_text] Cell and gene therapies (CGTs) offer an unprecedented opportunity to treat diseases for which existing interventions are inadequate, potentially offering cures for previously terminal illnesses. […]
October 24, 2018
RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam's Thirty Year Journey to First Approval

RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval

[vc_row][vc_column][vc_column_text]   In August 2018, the FDA & European Commission announced the approval of Alnylam Pharmaceutical’s ONPATTRO, a first-of-its-kind RNA interference (RNAi) therapeutic. Evolution Executive’s latest […]
October 10, 2018
Global Drug Development IPOs: 26 Companies Raise $3.18B in Q3 as First Pre-Revenue Biotechs List on HKEX

Global Drug Development IPOs: 26 Companies Raise $3.18B in Q3 as First Pre-Revenue Biotechs List on HKEX

[vc_row][vc_column][vc_column_text] The Drug Development IPO market enjoyed a strong third quarter, with over $3.18B raised by 26 companies across the globe, bringing the year-to-date total up […]
September 12, 2018

The Future of BioManufacturing: Automated Closed Systems for Cell & Gene Therapy Processes

August 10, 2018
Democratising DNA: 23andMe & GSK Collaboration Raises Privacy & Data Quality Concerns - Can Blockchain Offer a Disruptive Solution?

Democratising DNA: 23andMe & GSK Collaboration Highlights Data Quality & Privacy Concerns; Can Blockchain Offer a Disruptive Solution?

[vc_row][vc_column][vc_column_text] Personal genomics company 23andMe recently entered a four-year $500M collaborative agreement with major pharmaceutical company GlaxoSmithKline. The deal gives GSK access to the genetic data […]
July 12, 2018
Global Drug Development IPOs: NASDAQ Dominance Continues as 26 Companies Raise Over $2.54B in Q2

Global Drug Development IPOs: NASDAQ Dominance Continues as 26 Companies Raise Over $2.54B in Q2

[vc_row][vc_column][vc_column_text]The Drug Development IPO market enjoyed a strong second quarter, with over $2.54B raised by 26 companies across the globe. 85% of companies that listed during […]
June 4, 2018

The Future of BioManufacturing: In Silico Modelling

April 12, 2018
Lonza Opens World’s Largest Cell & Gene Therapy Manufacturing Plant in Texas

Lonza Opens World’s Largest Cell & Gene Therapy Manufacturing Plant in Texas

[vc_row][vc_column][vc_column_text] Swiss CDMO Lonza recently opened the world’s biggest manufacturing plant to produce custom viruses for use in cell and gene therapies. The facility, based in […]
March 27, 2018

All Eyes on Oxford Nanopore after further £100m funding raised at £1.5B Valuation

[vc_row][vc_column][vc_column_text] Oxford Nanopore recently announced that it has attracted a further £100M in funding. The latest investment round values Oxford Nanopore at £1.5B, with Singapore-based GIC, […]
Contact Us